Patents Issued in November 20, 2018
-
Patent number: 10130657Abstract: A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxidation therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.Type: GrantFiled: February 14, 2016Date of Patent: November 20, 2018Inventor: John C. Hughes
-
Patent number: 10130658Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: GrantFiled: December 18, 2015Date of Patent: November 20, 2018Assignees: Provectus Pharmatech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
-
Patent number: 10130659Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.Type: GrantFiled: February 8, 2018Date of Patent: November 20, 2018Assignee: IOVANCE BIOTHERAPEUTICS, INC.Inventors: Seth Wardell, James Bender, Michael T. Lotze
-
Patent number: 10130660Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.Type: GrantFiled: June 5, 2014Date of Patent: November 20, 2018Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Young-Bae Park, Hyo-Soo Kim, Hyun-Jae Kang, Jin Hur, Jeehoon Kang, Jung-Kyu Han, Ji-Yeon Yun, Jae-Il Choi, Jin-A Kang
-
Patent number: 10130661Abstract: The present invention provides devices and methods for improving wound healing, in particular, in diabetic subjects.Type: GrantFiled: May 11, 2015Date of Patent: November 20, 2018Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc., Trustees of Tufts CollegeInventors: Aristidis Veves, David J. Mooney, Jonathan Garlick
-
Patent number: 10130662Abstract: A delivery system for delivery of a therapeutic agent such as stem cells into a vein and across a micro circulation system into an artery comprises a multi lumen catheter for delivery of a therapeutic agent. A discharge device is located in a vein. The operation of the delivery device is controlled by a pressure stem cell solution delivery gun system. There are multiple delivery stages. These may include delivery of an elixir to open up the pressure bed, a platelet-rich plasma, stem cells, scaffolds, and finally an elixir to provide emichment and nourishment of the stem cells.Type: GrantFiled: October 20, 2014Date of Patent: November 20, 2018Assignee: Tulip Endovascular Innovation LimitedInventors: Sherif Sultan, Niamh Hynes
-
Patent number: 10130663Abstract: The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.Type: GrantFiled: February 10, 2016Date of Patent: November 20, 2018Assignee: The John Hopkins UniversityInventors: William R. Bishai, Ruchi Jain Dey, Bappaditya Dey, Laurene Cheung
-
Patent number: 10130664Abstract: The present invention relates probiotic compositions useful in accelerating alcohol catabolism in a subject.Type: GrantFiled: May 12, 2014Date of Patent: November 20, 2018Assignee: BiOWiSH Technologies, Inc.Inventors: Richard Carpenter, Amit Kapur, E. Wesley Huff, Narayan Suresh
-
Patent number: 10130665Abstract: A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harboring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture.Type: GrantFiled: May 20, 2013Date of Patent: November 20, 2018Assignee: GENOME RESEARCH LIMITEDInventors: Trevor D. Lawley, Simon Clare, Gordon Dougan
-
Patent number: 10130666Abstract: The present invention provides Lactobacillus plantarum CJLP133 KCTC 11403BP, a composition for treating intestinal diseases comprising the lactic acid bacteria, and a composition for enhancing immunity comprising the lactic acid bacteria.Type: GrantFiled: August 21, 2015Date of Patent: November 20, 2018Assignee: CJ CHEILJEDANG CORPInventors: Bong Joon Kim, Heon Woong Jung, Se Hee Hwang, Jin Hee Lee, Kang-Pyo Lee, Kwang Woo Hwang, Tae Joon Won
-
Patent number: 10130667Abstract: The present invention relates to a vaccine comprising the insertion of three genes, the TAA/ecdCD40L EA1 and CDA, driven by promoters L-plastin/cytosinedeaminase and CMV as a three gene, three transcription unit oncolytic virus as a conditionally replication competent adenoviral vector which replicates only in tumor cells. In these transcription units, the E1A gene of the adenoviral vector as well as the cytosine deaminase gene are under the control of the L-plastin promoter, while the TAA/ecdCD40L transcription unit is under control of a the CMV promoter.Type: GrantFiled: April 15, 2016Date of Patent: November 20, 2018Assignee: MicroVAX, LLCInventor: Albert B. Deisseroth
-
Patent number: 10130668Abstract: Provided is a use of Dendropanax morbifera extract as an agent for preventing and treating benign prostatic hyperplasia, and more particularly, a composition for preventing and treating benign prostatic hyperplasia and a functional health food for preventing and reducing the effects of benign prostatic hyperplasia, in which the composition and food include, as an active ingredient, a Dendropanax morbifera extract or a compound which is isolated from the extract and then purified.Type: GrantFiled: January 30, 2013Date of Patent: November 20, 2018Assignee: Industry-Academic Cooperation Foundation, Chosun UniversityInventors: Cheol-Hee Choi, Young-Sook Moon, Ju-Hee Han, Kyoung-In Lee, Hyun-Jung Kim
-
Patent number: 10130669Abstract: A method and a system comprise receiving an amount of a first disinfecting solution on and around a wound. An amount of a second disinfecting solution is received on and around the wound. An amount of a third disinfecting solution is received on and around the wound. An amount of a fourth disinfecting solution is received around the wound. Cold laser emissions are received on and around the wound. The cold laser emissions comprise at least multiple wavelengths. A sterile gauze bandage and wrap cover the wound.Type: GrantFiled: December 29, 2014Date of Patent: November 20, 2018Inventor: Ronald K. Gilbert
-
Patent number: 10130670Abstract: The present invention relates to a composition for treating or preventing an inflammatory skin disease, comprising, as an active ingredient, an unripe Citrus unshiu fruit extract and/or Synephrine or salt thereof. The composition of the present invention prevents an inflammatory reaction by inhibiting activity of STAT6, expression of eotaxin-1 and an agglomeration function of eosinophil, and thus, shows effects of preventing and treating an allergic inflammatory disease, atopic dermatitis, eczema, psoriasis, etc. Also, the composition of the present invention does not have cytotoxicity and a skin side effect, and thus, can be safely applied to pharmaceutical products and cosmetics.Type: GrantFiled: June 19, 2014Date of Patent: November 20, 2018Assignee: BIOSPECTRUM, INC.Inventors: Kyung Baeg Roh, Young Soo Kim, Eun Sun Jung, Deok Hoon Park
-
Patent number: 10130671Abstract: Embodiments described herein provide for uses of grape products, such as Chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing NAFLD, and other embodiments and uses as described herein.Type: GrantFiled: December 18, 2015Date of Patent: November 20, 2018Assignees: SONOMACEUTICALS, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Torey James Arvik, Hyunsook Kim, Wallace H. Yokoyama, Scott R. Forsberg
-
Patent number: 10130672Abstract: The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs.Type: GrantFiled: October 1, 2012Date of Patent: November 20, 2018Assignee: Malaysian Palm Oil BoardInventors: Ravigadevi Sambanthamurthi, Kalyana Sundram P. Manickam, Yew Ai Tan, Mohd Basri bin Wahid
-
Patent number: 10130673Abstract: A method of reducing TNF-? production in human epidermal keratinocytes, the method comprising topically applying to skin in need thereof a composition comprising an effective amount of a liquid kakadu plum extract comprising kakadu plum fruit, alcohol, and butylene glycol to reduce TNF-? production in human epidermal keratinocytes of the skin, and an effective amount of a liquid acai berry extract comprising acai berry fruit, water, and alcohol to reduce TNF-? production in human epidermal keratinocytes of the skin.Type: GrantFiled: October 3, 2016Date of Patent: November 20, 2018Assignee: Mary Kay Inc.Inventors: David Gan, Michelle Hines, Javier Aravena, Brian Jones
-
Patent number: 10130674Abstract: Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT (SEQ ID NO:1) exhibits potent antagonism for both CCR2 (IC50 4.2 pM) and CCR5 (IC50 0.18 pM) in monocyte chemotaxis. Oral administration of All D TTNYT (SEQ ID NO:1) (0.05-1 mg/kg) for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia following partial ligation of the sciatic nerve in rats. Administered from day 8 to day 12, All D TTNYT (SEQ ID NO:1) (0.2-1 mg/kg) reverses already established hypersensitivity.Type: GrantFiled: February 10, 2011Date of Patent: November 20, 2018Assignee: Creative Bio-PeptidesInventors: Candace Pert, Michael Ruff
-
Patent number: 10130675Abstract: The present invention aims to provide a wound healing agent that inhibits bacterial growth, promotes granulation tissue formation and epithelization, and minimizes foreign body reaction in the granulation tissue. The wound healing agent of the present invention contains protein (A) and water, wherein the protein (A) contains: GAGAGS (1); and an amino acid sequence (X) and/or an amino acid sequence (X?), and the total percentage of ? turns and random coils in the protein (A) as determined by circular dichroism spectroscopy is 60 to 85%, and the percentage of the total number of amino acid residues in the amino acid sequences (X) and (X?) is 50 to 70% of the total number of amino acid residues in the protein (A). Amino acid sequence (X): at least one amino acid sequence selected from the group consisting of VPGVG (2), GVGVP (3), and GAHGPAGPK (4).Type: GrantFiled: February 20, 2014Date of Patent: November 20, 2018Assignee: SANYO CHEMICAL INDUSTRIES, LTD.Inventor: Shingo Kawabata
-
Patent number: 10130676Abstract: The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, or variants, mutants, derivatives, or fragments thereof.Type: GrantFiled: April 16, 2015Date of Patent: November 20, 2018Assignee: Prime Bio-Drug Development LimitedInventor: Chen-Lung Lin
-
Patent number: 10130677Abstract: The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.Type: GrantFiled: December 12, 2014Date of Patent: November 20, 2018Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Academisch Medisch CentrumInventors: Petrus Hendricus Nibbering, Anna de Breij, Robert Alexander Cordfunke, Sebastianus Antonius Johannes Zaat, Jan Wouter Drijfhout
-
Patent number: 10130678Abstract: Systems and methods for preparing synthetic osteoinductive bone grafts are provided in which a porous ceramic granule, which may be incorporated within a biocompatible matrix material, is loaded with an osteoinductive agent. Loading of granules is facilitated in some cases by the use of low-pH buffers and pre-treatments.Type: GrantFiled: December 29, 2015Date of Patent: November 20, 2018Assignee: Bioventus, LLC.Inventors: Eric Vanderploeg, Howard Seeherman, Christopher G. Wilson, John Wozney, Christopher T. Brown, John A. Kambouris
-
Patent number: 10130679Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.Type: GrantFiled: March 18, 2016Date of Patent: November 20, 2018Assignee: University of MassachusettsInventors: Michael R. Green, Guangping Gao, Manas Kumar Santra, Sanchita Bhatnagar
-
Patent number: 10130680Abstract: The technology described herein is directed to methods and compositions directed to the treatment of cancer, e.g. using multifunctional receptor targeted cancer therapeutics.Type: GrantFiled: February 7, 2017Date of Patent: November 20, 2018Assignee: THE GENERAL HOSPITAL CORPORATIONInventor: Khalid Shah
-
Patent number: 10130681Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: March 28, 2017Date of Patent: November 20, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: George D. Yancopoulos
-
Patent number: 10130682Abstract: A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo.Type: GrantFiled: March 30, 2015Date of Patent: November 20, 2018Assignees: Ramot at Tel-Aviv University Ltd., Mor Research Applications Ltd.Inventors: Ruth Shalgi, Dana Chuderland, Hadas Bar-Joseph, Keren Goldberg, Irit Ben-Aharon, Salomon M. Stemmer
-
Patent number: 10130683Abstract: A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions.Type: GrantFiled: August 11, 2015Date of Patent: November 20, 2018Assignee: University of South FloridaInventors: Cesario Venturina Borlongan, Paul R. Sanberg
-
Patent number: 10130684Abstract: Provided are orally administrable thin film dosage forms adapted to adhere to a mucosal tissue of a patient, wherein said film comprises mixtures of polymers and insulin.Type: GrantFiled: January 30, 2012Date of Patent: November 20, 2018Assignee: PHARMEDICA LTD.Inventors: Yoram Rubin, Smadar Cohen, Eyal S. Ron
-
Patent number: 10130685Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: GrantFiled: June 9, 2017Date of Patent: November 20, 2018Assignee: MannKind CorporationInventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 10130686Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.Type: GrantFiled: November 21, 2016Date of Patent: November 20, 2018Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Paul J. Davis
-
Patent number: 10130687Abstract: Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment.Type: GrantFiled: January 5, 2012Date of Patent: November 20, 2018Assignee: Rhode Island HospitalInventors: Qian Chen, Chathuraka T. Jayasuriya
-
Patent number: 10130688Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.Type: GrantFiled: June 7, 2017Date of Patent: November 20, 2018Assignee: Applied Molecular Transport Inc.Inventors: Randall Mrsny, Tahir Mahmood
-
Patent number: 10130689Abstract: The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.Type: GrantFiled: June 22, 2010Date of Patent: November 20, 2018Assignee: DIFFUSION PHARMACEUTICALS LLCInventor: John L. Gainer
-
Patent number: 10130690Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.Type: GrantFiled: December 11, 2017Date of Patent: November 20, 2018Assignee: Shire ViroPharma IncorporatedInventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
-
Patent number: 10130691Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.Type: GrantFiled: March 14, 2014Date of Patent: November 20, 2018Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
-
Patent number: 10130692Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.Type: GrantFiled: January 26, 2012Date of Patent: November 20, 2018Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Patent number: 10130693Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 26, 2016Date of Patent: November 20, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10130694Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.Type: GrantFiled: May 26, 2017Date of Patent: November 20, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
-
Patent number: 10130695Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.Type: GrantFiled: August 18, 2017Date of Patent: November 20, 2018Assignees: Vedanta Biosciences, Inc., RIKENInventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
-
Patent number: 10130696Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: September 18, 2008Date of Patent: November 20, 2018Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
-
Patent number: 10130697Abstract: The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain.Type: GrantFiled: March 23, 2011Date of Patent: November 20, 2018Assignee: Wisconsin Alumni Research Foundation (WARF)Inventors: Shinji Watanabe, Tokiko Watanabe, Yoshihiro Kawaoka
-
Patent number: 10130698Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.Type: GrantFiled: December 2, 2014Date of Patent: November 20, 2018Assignee: Intervet Inc.Inventors: Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
-
Patent number: 10130699Abstract: The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.Type: GrantFiled: December 2, 2014Date of Patent: November 20, 2018Assignee: Intervet Inc.Inventors: Antonius Arnoldus Christiaan Jacobs, Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
-
Patent number: 10130700Abstract: This disclosure provides compositions that include a mixture of viral like particles (VLPs), expressing different individual influenza hemagglutinin (HA) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza VLPs, a first VLP comprising a first HA polypeptide and a second VLP comprising a second influenza HA polypeptide, wherein the first and the second HA polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant. Methods of using the disclosed polymeric influenza VLP compositions to stimulate an immune response against influenza viruses, for example as a pre-pandemic or a seasonal vaccine, are provided.Type: GrantFiled: May 8, 2015Date of Patent: November 20, 2018Assignee: The United States of America, as represented by the Secretary, DHHSInventor: Jeffery K. Taubenberger
-
Patent number: 10130701Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.Type: GrantFiled: July 23, 2015Date of Patent: November 20, 2018Assignee: THE PIRBRIGHT INSTITUTEInventors: Erica Bickerton, Sarah Keep, Paul Britton
-
Patent number: 10130702Abstract: The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.Type: GrantFiled: January 31, 2018Date of Patent: November 20, 2018Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.Inventors: Kegong Tian, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
-
Patent number: 10130703Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: GrantFiled: May 8, 2015Date of Patent: November 20, 2018Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventor: Konstantin G. Kousoulas
-
Patent number: 10130704Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: GrantFiled: December 16, 2016Date of Patent: November 20, 2018Assignee: ONDEK PTY LTDInventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Patent number: 10130705Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.Type: GrantFiled: October 2, 2014Date of Patent: November 20, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
-
Patent number: 10130706Abstract: The present disclosure provides topical biophotonic materials and methods useful in phototherapy. In particular, the topical biophotonic materials of the present disclosure include a cohesive matrix, and at least chromophore which can absorb and emit light from within the topical biphotonic material, wherein the topical biophotonic material is elastic. The topical biophotonic materials and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various other skin disorders.Type: GrantFiled: March 14, 2014Date of Patent: November 20, 2018Assignee: KLOX TECHNOLOGIES INC.Inventors: Nikolaos Loupis, Remigio Piergallini, Éric DesRosiers